Antimitotic drugs in cancer chemotherapy: Promises and pitfalls

被引：74

作者：

Marzo, Isabel ^{[1
]}

Naval, Javier ^{[1
]}

机构：

[1] Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, Zaragoza 50009, Spain

来源：

BIOCHEMICAL PHARMACOLOGY | 2013年 / 86卷 / 06期

关键词：

Mitosis; Cancer; Chemotherapy; DEPENDENT KINASE INHIBITOR; SPINDLE PROTEIN INHIBITOR; SMALL-MOLECULE INHIBITOR; RESISTANT PROSTATE-CANCER; PHASE-I; ANTITUMOR-ACTIVITY; AURORA KINASE; DOSE-ESCALATION; MITOTIC ARREST; CDK INHIBITOR;

D O I：

10.1016/j.bcp.2013.07.010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer cells usually display higher proliferation rates than normal cells. Some currently used antitumor drugs, such as vinca alkaloids and taxanes, act by targeting microtubules and inhibiting mitosis. In the last years, different mitotic regulators have been proposed as drug target candidates for antitumor therapies. In particular, inhibitors of Cdks, Chks, Aurora kinase and Polo-like kinase have been synthesized and evaluated in vitro and in animal models and some of them have reached clinical trials. However, to date, none of these inhibitors has been still approved for use in chemotherapy regimes. We will discuss here the most recent preclinical information on those new antimitotic drugs, as well as the possible molecular bases underlying their lack of clinical efficiency. Also, advances in the identification of other mitosis-related targets will be also summarized. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：703 / 710

页数：8

共 89 条

[1] Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor [J].

Alvarez-Fernandez, Stela ;

Jesus Ortiz-Ruiz, Maria ;

Parrott, Tracy ;

Zaknoen, Sara ;

Ocio, Enrique M. ;

San Miguel, Jesus ;

Burrows, Francis J. ;

Esparis-Ogando, Azucena ;

Pandiella, Atanasio .

CLINICAL CANCER RESEARCH, 2013, 19 (10) :2677-2687

[2] SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo [J].

Arbitrario, Jennifer P. ;

Belmont, Brian J. ;

Evanchik, Marc J. ;

Flanagan, W. Michael ;

Fucini, Raymond V. ;

Hansen, Stig K. ;

Harris, Shannon O. ;

Hashash, Ahmad ;

Hoch, Ute ;

Hogan, Jennifer N. ;

Howlett, Anthony R. ;

Jacobs, Jeffrey W. ;

Lam, Joni W. ;

Ritchie, Sean C. ;

Romanowski, Michael J. ;

Silverman, Jeffrey A. ;

Stockett, David E. ;

Teague, Juli N. ;

Zimmerman, Kristin M. ;

Taverna, Pietro .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) :707-717

[3] A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies [J].

Arkenau, H. -T. ;

Plummer, R. ;

Molife, L. R. ;

Olmos, D. ;

Yap, T. A. ;

Squires, M. ;

Lewis, S. ;

Lock, V. ;

Yule, M. ;

Lyons, J. ;

Calvert, H. ;

Judson, I. .

ANNALS OF ONCOLOGY, 2012, 23 (05) :1307-1313

[4] Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors [J].

Boss, D. S. ;

Witteveen, P. O. ;

van der Sar, J. ;

Lolkema, M. P. ;

Voest, E. E. ;

Stockman, P. K. ;

Ataman, O. ;

Wilson, D. ;

Das, S. ;

Schellens, J. H. .

ANNALS OF ONCOLOGY, 2011, 22 (02) :431-437

[5] Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint [J].

Brito, Daniela A. ;

Rieder, Conly L. .

CURRENT BIOLOGY, 2006, 16 (12) :1194-1200

[6] A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors [J].

Burris, Howard A., III ;

Jones, Suzanne F. ;

Williams, Daphne D. ;

Kathman, Steven J. ;

Hodge, Jeffrey P. ;

Pandite, Lini ;

Ho, Peter T. C. ;

Boerner, Scott A. ;

LoRusso, Patricia .

INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) :467-472

[7] Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors [J].

Cervantes, Andres ;

Elez, Elena ;

Roda, Desamparados ;

Ecsedy, Jeffrey ;

Macarulla, Teresa ;

Venkatakrishnan, Karthik ;

Rosello, Susana ;

Andreu, Jordi ;

Jung, JungAh ;

Sanchis-Garcia, Juan Manuel ;

Piera, Adelaida ;

Blasco, Inma ;

Manos, Laura ;

Perez-Fidalgo, Jose-Alejandro ;

Fingert, Howard ;

Baselga, Jose ;

Tabernero, Josep .

CLINICAL CANCER RESEARCH, 2012, 18 (17) :4764-4774

[8] Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia [J].

Chen, Jing ;

Pise-Masison, Cynthia A. ;

Shih, Joanna H. ;

Morris, John C. ;

Janik, John E. ;

Conlon, Kevin C. ;

Keating, Anne ;

Waldmann, Thomas A. .

BLOOD, 2013, 121 (11) :2029-2037

[9] Inhibition of Eg5 Acts Synergistically with Checkpoint Abrogation in Promoting Mitotic Catastrophe [J].

Chen, Yue ;

Chow, Jeremy P. H. ;

Poon, Randy Y. C. .

MOLECULAR CANCER RESEARCH, 2012, 10 (05) :626-635

[10] Ibulocydine Is a Novel Prodrug Cdk Inhibitor That Effectively Induces Apoptosis in Hepatocellular Carcinoma Cells [J].

Cho, Seung-Ju ;

Kim, Young-Jong ;

Surh, Young-Joon ;

Kim, B. Moon ;

Lee, Seung-Ki .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (22) :19662-19671

← 1 2 3 4 5 6 7 8 9 →